JP Morgan Maintains Neutral on Terns Pharma, Raises Price Target to $11
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Eric Joseph maintains a Neutral rating on Terns Pharma (NASDAQ:TERN) and raises the price target from $10 to $11.
August 09, 2023 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains a Neutral rating on Terns Pharma and raises the price target from $10 to $11. This could potentially lead to a slight increase in the stock's price.
The raised price target by JP Morgan indicates a positive outlook for Terns Pharma. While the Neutral rating suggests no significant changes, the increased price target could lead to a slight increase in the stock's price as it indicates the analyst's increased confidence in the company's performance.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100